[New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2]

Marie-Sophie Minot-This; Audrey Bellesoeur

doi:10.1016/j.bulcan.2021.05.001

[New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2]

Bull Cancer. 2021 Sep;108(9):783-784. doi: 10.1016/j.bulcan.2021.05.001. Epub 2021 Jun 16.

[Article in French]

Authors

Marie-Sophie Minot-This¹, Audrey Bellesoeur²

Affiliations

¹ Institut Gustave-Roussy, département d'oncologie digestive, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: ms.minot@gmail.com.
² Institut Curie, département d'oncologie médicale, 26, rue Ulm, 75005 Paris, France; Institut Curie, département de radio-pharmacologie, 35, rue Dailly, 92210 Saint-Cloud, France.

PMID: 34144792
DOI: 10.1016/j.bulcan.2021.05.001

No abstract available

Keywords: Anti-HER2; Anti-HER2 treatment; Anticorps monoclonal; Cancer du sein HER2 positif; Cancer du sein métastatique; HER2-positive breast carcinoma; Metastatic breast carcinoma; Monoclonal antibody; Traitement anti-HER2.

Publication types

News

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Breast Neoplasms / chemistry
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Camptothecin / analogs & derivatives*
Camptothecin / therapeutic use
Clinical Trials, Phase II as Topic
Drug Approval*
Female
Humans
Immunoconjugates / therapeutic use*
Multicenter Studies as Topic
Receptor, ErbB-2* / antagonists & inhibitors
Trastuzumab / therapeutic use*

Substances

Antineoplastic Agents, Immunological
Immunoconjugates
trastuzumab deruxtecan
Receptor, ErbB-2
Trastuzumab
Camptothecin